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Inline Spiking Method for Validating Continuous Virus Filtration
Herb Lutz (principal consulting engineer BSN process solutions)
Introduction

Inline Qualification with salt spike

Conventional virus filtration (VF) processes involve batch
processing a uniform feed at uniform conditions (e.g. constant
pressure). Continuous VF processes can involve an elutiion
protein peak with a salt gradient under non-uniform pressure
where standard spiking methodologies do not represent the
manufacturing process as required by the ICH Q5A virus
validation guidelines.

Salt spike improves sensitivity of concentration
measurements: 2x difference in salt concentration
(conductivity) corresponds to a 0.3 difference in log10 scales.
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This paper describes the development, qualification, and
implementation of an inline spiking methodology that is suitable
for validating continuous processes.
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to ensure comparable
residence times for plugging
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Measure virus removal
using scaled down
models that mirror large
scale production to
ensure that the virus
removal results can be
translated to the
biotherapeutic product.
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MMV plugging due to protein. xMuLV plugging due to
protein+spike. 2-4x capacity increases with inline spiking (even
with xMuLV spike )
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Inline qualification with prefiltration

Batch virus filtration
Add virus spike to batch
prefiltered product. Filter
spiked solution with 0.2 or
0.45mm membranes. Perform
virus filtration, sample filtrate
weight at regular time points

Flush filters with water and
buffer. Add 0.2 mm filtered
protein solution to the feed
vessel and 0.2 mm filtered
spiking solution to the feed
syringe pump. Pressurize
feed vessel, open valves.
Start syringe pump to
continuously inject spike,
mix with refiltered feed,
sample, and feed to virus
filter. Measure filtrate
weight vs time & calculate
flow rate. As the virus filter
plugs and flow drops, slow
down the syringe pump to
maintain % spiking ratio
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Run to run variability was <6%. Sample syringe titer can be
used as feed pool titer. Sample syringe and filtrate within
14% (0.07 log10 units or ~0 LRV). The predicted
filtrate/sample syringe titer within 9% (Hold control ~0
LRV). Well mixed solution so sample syringe is
representative of cross section. Mass balance closes &
holdup volumes are negligible

Figure 1: Standard spiking system
a) Batch prefiltration, b) Batch virus filtration
Compressed Air Tank
with Pressure
Regulator at 4-5 psi

0.68
0.68
0.68
0.68
0.68
0.68

Flux (LMH)

Standard spiking

Spike
(M)

Predicted
Filtrate/Sample
Syringe (M)
0.028
0.029
0.026
0.070
0.069
0.068

Linked processing

Method allows
for spiking
during elution
segments.
Amgen CEX
data indicates
virus load
uniform across
elution to lag
behind elution.

MuLV elution from upstream CEX a) pH5, b) pH6

Summary
Inline spiking methodology:
 Improves filter throughputs
 More representative of manufacturing inline operation
 Demonstrates virus LRV comparable to standard
spiking
 Consistent
 Relatively easy to operate
 Useful where proteins form plugging foulants
 Facilitates validation of linked processes
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Inline spiking shows comparable LRV to standard spiking.
Inline spiking shows improved filtrate throughput
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